NTX-1034C

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNTX-1034C

Drug Alias Nameanti-CD155 CAR T/NK-cell therapy (Nectin Therapeutics)NTX-1034C

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionPoliovirus receptor modulators

TargetsPoliovirus receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNectin Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNectin Therapeutics Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A